Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vistagen Therapeutics Inc    VTGN

VISTAGEN THERAPEUTICS INC (VTGN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 04:00:00 pm
1.68 USD   +1.20%
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Regulation FD Disclosure

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:40pm EST

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

On January 7, 2019, VistaGen Therapeutics, Inc. (the“Company”) began utilizing a new corporate presentation. A copy of the Corporate Presentation is attached hereto as Exhibit99.1.

The information in this Item 7.01 of this Current Report onForm8-K,including the information set forth in Exhibit99.1, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

In addition, this Current Report on Form 8-K and the exhibit(s) attached hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company’s plans, objectives, expectations and intentions; and (ii) other statements identified by words such as “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties.

Item 9.01 Exhibits.

See Exhibit Index.

VistaGen Therapeutics, Inc. Exhibit

To view the full exhibit click here

About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.

The post VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Regulation FD Disclosure appeared first on Market Exclusive.

© Market Exclusive 2019, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VISTAGEN THERAPEUTICS INC
01/16VISTAGEN THERAPEUTICS : Appoints Pharmaceutical Industry Veteran, Ann Cunningham..
AQ
01/15VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningha..
GL
01/11VISTAGEN THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
2018VISTAGEN THERAPEUTICS : to Present at 11th Annual Biotech Showcase
AQ
2018VISTAGEN THERAPEUTICS : Unregistered Sale of Equity Securities (form 8-K/A)
AQ
2018VISTAGEN THERAPEUTICS : Receives Hong Kong Patent for Methods of Production for ..
AQ
2018VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for..
GL
2018VISTAGEN THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (f..
AQ
2018VISTAGEN THERAPEUTICS : Receives Notices of Allowance in Australia and Japan for..
AQ
2018VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan fo..
GL
More news
Financials ($)
Sales 2019 -
EBIT 2019 -23,0 M
Net income 2019 -23,3 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 0
Capi. / Sales 2020 0
Capitalization 52,2 M
Chart VISTAGEN THERAPEUTICS INC
Duration : Period :
Vistagen Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VISTAGEN THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 11,3 $
Spread / Average Target 575%
EPS Revisions
Managers
NameTitle
Shawn K. Singh Chief Executive Officer & Director
H. Ralph Snodgrass President, Director & Chief Scientific Officer
Jon Sheldon Saxe Chairman
Jerrold D. Dotson Chief Financial Officer, Secretary & VP
Mark A. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VISTAGEN THERAPEUTICS INC12.00%52
BIOGEN12.13%67 984
CSL LIMITED5.96%63 903
ALEXION PHARMACEUTICALS20.22%26 113
BIOMARIN PHARMACEUTICAL14.52%17 395
GRIFOLS6.72%16 880